Fri, Dec 26, 2014, 1:18 AM EST - U.S. Markets open in 8 hrs 12 mins

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

checksurshorts 27 posts  |  Last Activity: Dec 4, 2014 7:27 PM Member since: Dec 1, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • He could have "saved" Shire from buying the rights to "failed" FDA approved (for SS) Iplex for this indication:IGF-1/IGFBP3 for the Prevention of Retinopathy of Prematurity.

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Nov 10, 2014 9:53 PM Flag

    METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC SYNDROME, OBSTRUCTIVE RESPIRATORY DISORDERS, CANCER AND RELATED DISEASES

    Dr. Oh's patent app has been updated 9/25/14 United States Patent Application 20140286966

    Been keeping an eye on this for a while. IGFBP-3 for asthma, etc...

    Also, from the application: "A vector may also include or be associated with various materials to aid in its entry into the cell, including but not limited to a virion, a liposome, or a protein coating"

    Who knows if this will go anywhere but worth keeping an eye on.

    IGFBP-3 is outside of the settlement.

    Sentiment: Strong Buy

  • Reply to

    Conference Call today

    by blasedp31 Nov 6, 2014 7:35 PM
    checksurshorts checksurshorts Nov 6, 2014 10:11 PM Flag

    "What was interesting was the fact that Lewis said the Phase 3 Trial endpoints are the same ones used in Tuberculosis trial developments. Why would Insmed do that?"

    Executive amnesty would bring more than just Democrat voters. IMHO

    Sentiment: Strong Buy

  • Reply to

    New Job Posting.....

    by insmhistorian Oct 30, 2014 1:30 PM
    checksurshorts checksurshorts Oct 30, 2014 11:17 PM Flag

    London.

    Mind the gap -- up!

    Sentiment: Strong Buy

  • Reply to

    Has anyone noticed ?

    by jad90000 Oct 11, 2014 10:49 AM
    checksurshorts checksurshorts Oct 11, 2014 11:07 AM Flag

    A clone that posts just as Rhdvm would...hmmm

    Sentiment: Strong Buy

  • Reply to

    Who should we believe?

    by bohemianclubman Sep 4, 2014 1:11 PM
    checksurshorts checksurshorts Sep 4, 2014 11:59 PM Flag

    Hmmm...I can't help but think that if Insmed were merely courting big pharma, its next target would have encompassed a much broader market. Perhaps we are in this for the long haul?

    Sentiment: Strong Buy

  • Reply to

    From NTM Forum

    by checksurshorts Aug 19, 2014 9:58 AM
    checksurshorts checksurshorts Aug 19, 2014 10:18 AM Flag

    From what I understand, Abscessus is a really tough bug to eradicate.

    Sentiment: Strong Buy

  • Reply to

    From NTM Forum

    by checksurshorts Aug 19, 2014 9:58 AM
    checksurshorts checksurshorts Aug 19, 2014 10:10 AM Flag

    "Arikace was awesome. Have you heard much about it? For the phase 2 trial I was on, I think something like 25% of the (treatment refractory) participants were culture negative at the end of the trial. I think if I could have stayed on it longer, I would have gotten there too. Now all I can do is pray that it gets FDA approval soon! The FDA did designate it as a "breakthrough therapy" after the trial results came out, but I don't really know what that will mean in terms of FDA approval. If they need to go through a phase 3 trial, I think we'll still be at least a few years away from it being readily available."

    "Yeah I heard a bit about it, very promising results! I am off meds & culture negative and hope to stay that way forever, but I've seen so many reports on this forum about people who relapsed that it is a comforting thought that new treatments are being developed. I hope FDA approval comes soon for people like you & others who need it."

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Aug 19, 2014 9:58 AM Flag

    "Hi all,

    After a glorious one-year drug holiday, I am about to re-start therapy for M. Abscessus. One of the drugs my docs are going to try this time is Clofazimine. Has anyone on here ever taken it? I know it's a longshot, but I'm hoping someone has, and can perhaps share his/her experience.

    I'm well aware that it causes skin discoloration, and I also know that some people develop gastrointestinal issues. But, I'm trying to understand what this really means for patients who have taken it. I totally trust my doctors, though I know they want me to take it, so I wouldn't be too surprised (and also wouldn't blame them) if they've downplayed the side effects a bit. And of course, if you google it, you can find all sorts of ridiculously terrible results. So, I'm seeking some real-life experience."

    [SNIP]

    "I don't really keep in touch with anyone else who has Abscessus, so I don't know how others are doing. Though I've been on and off drugs since I was diagnosed in 2007, I've done pretty well. I've been smear positive much of the time, but am still pretty healthy and have maintained my lung function. I've taken a mix of IV and oral drugs during that time, though the thing that made the most difference for me was taking part in the Arikace clinical trial. I was actually smear negative (though still culture positive) for about six months after the trial, which was a minor miracle for me."

    Sentiment: Strong Buy

  • And the bashers come alive again.

    Sentiment: Strong Buy

  • Reply to

    Negative at last (since it was removed)

    by checksurshorts Apr 5, 2014 12:01 PM
    checksurshorts checksurshorts Aug 14, 2014 8:34 PM Flag

    I see I have a clone. Hoping for a speedy p-III based upon above.

    Sentiment: Strong Buy

  • Reply to

    Slowly . . .

    by rehdvm2004 Aug 9, 2014 4:59 PM
    checksurshorts checksurshorts Aug 10, 2014 1:25 PM Flag

    Great, you can disappear for 9.5 years or so.

    Sentiment: Strong Buy

  • Reply to

    Will New Trial be Halted Early?

    by checksurshorts Aug 5, 2014 12:04 PM
    checksurshorts checksurshorts Aug 5, 2014 4:01 PM Flag

    Here is why I think you are wrong Terryoda. Why not just redo the trial with only the endpoint change? Instead they are able to do it with the patients who best responded to the treatment -- MAC patients. It's like the FDA is saying "you have to catch one more fish" while practically putting one on the hook for them.

  • Reply to

    Will New Trial be Halted Early?

    by checksurshorts Aug 5, 2014 12:04 PM
    checksurshorts checksurshorts Aug 5, 2014 12:10 PM Flag

    BTW...isn't there a little girl out there that is still alive and with a new set of lungs only because public outcry forced the FDA to bend a little and set precedent?

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Aug 5, 2014 12:04 PM Flag

    Will this be a very, very short trial that ends up being halted due to positive results? Duplicating positive results under a primary endpoint of culture conversion will prevent the FDA from having to set a precedent (Heaven forbid). Maybe that is all they are looking for? The conversion was occurring at a rapid rate. The full NTM population trial would then just run its course for future label expansion. IMHO

    "The Company also plans to initiate a second Phase 3 study which will be designed to confirm, in as short a timeframe as possible, the positive culture conversion results seen in the Phase 2 study. This confirmatory study will primarily investigate ARIKAYCE for use in the treatment refractory population with mycobacterium avium complex (MAC) NTM lung infections. This subgroup of the Phase 2 trial’s patients responded particularly strongly to the treatment."

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Jul 31, 2014 4:58 PM Flag

    Steven Cohen billionaire hedge fund guy appears to be in. Haven't fully read yet.

    Sentiment: Strong Buy

  • checksurshorts checksurshorts Jul 27, 2014 4:17 PM Flag

    Thanks!

    "The Phase II and III clinical trials for aerosolized liposomal amikacin or ciprofloxacin for the treatment of P. aeruginosa lung infections in CF and non-CF bronchiectasis patients are evidence that demonstrate that in the next few years the liposome-based antibiotic-delivery systems will prove to be remarkable treatment alternatives for infectious diseases. For P. aeruginosa lung infections, the inhalational route of administration of liposomal antibiotic formula- tions has the potential to increase patient compliance, reduce the duration of the antibiotic treatment and possibly decrease the likelihood of bacterial resistance. The unique properties of liposomes will provide many opportunities to develop a wide range of liposomes to offer a clinically proven, biocompatible versatile plat- form for the enhancement of pharmacological efficacy of antibiotics. It is anticipated that in the next few years, liposomes may be used to deliver a combination of anti- biotic agents (i.e., aminoglycoside and β-lactam) or an antibacterial agent and an inhibitor of a major resistance mechanism (i.e., β-lactam and β-lactamase inhibitor). Also, liposomes that specifically target bacterial cells may be engineered by attaching amino acid fragments, such as antibodies or proteins or appropriate fragments that target specific sites in bacteria. It is envisioned that the future of liposomal antibiotic development is bright with a number of these lipid-based products proving to be remarkable treatment alternatives in the treatment of P. aeruginosa lung infections. "

    Sentiment: Strong Buy

  • Reply to

    NTMir Joins NORD

    by checksurshorts Jul 23, 2014 5:56 PM
    checksurshorts checksurshorts Jul 24, 2014 12:26 AM Flag

    If the NTM trial "failed" why do you think the FDA awarded breakthrough status based upon same trial? TIA

    Sentiment: Strong Buy

  • Reply to

    Upcoming Insmed headline soon?

    by insmhistorian Jul 23, 2014 4:10 PM
    checksurshorts checksurshorts Jul 23, 2014 6:03 PM Flag

    Love it!!!

    Sentiment: Strong Buy

  • checksurshorts by checksurshorts Jul 23, 2014 5:56 PM Flag

    "NTM Info & Research has joined the National Organization for Rare Diseases (NORD) as an associate member organization.

    A 501(c)(3) not-for-profit organization, NORD is a unique federation of health organizations dedicated to helping the more than 30 million Americans who live with a rare disease, and assisting the organizations that serve them.

    Founded by leaders of rare-disease organizations who helped shape the Orphan Drug Act, NORD is committed to the identification, treatment, and cure of rare disorders through programs of education, advocacy, research, and service.

    NORD offers several programs to help patients with rare diseases, including a Patient Assistance Program, Patient Information Center, Online Patient Communities, and State-by-State Insurance Information."

    Sentiment: Strong Buy

INSM
15.29+0.15(+0.99%)Dec 24 1:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Virgin America Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST
Gilead Sciences Inc.
NASDAQWed, Dec 24, 2014 1:00 PM EST